Portal vein thrombosis : a case report and literature review by Gauci, James et al.
  
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 25 Issue 03 2013                                                                                                 
 
 
 
 
Introduction 
 A case report of Portal Vein Thrombosis (PVT) as 
a complication of protein S deficiency. PVT has been 
increasingly diagnosed over the years, particularly 
through the use of ultrasound-Doppler equipment. The 
lifetime risk of getting PVT in the general population 
has recently reported to be 1%.
1
 While this condition 
has traditionally been associated with cirrhosis or liver 
malignancy, it may also occur without any liver 
disease.  
 The case report is followed by a discussion of the 
aetiology and clinical presentations of PVT, as well as 
a review of the investigations and management 
proposed in the literature. 
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Case Report 
A 36 year old lady was referred with non-specific 
abdominal pain, elevated liver enzymes and a 
prolonged INR. Abdominal examination revealed 
hepatosplenomegaly, which was confirmed on 
ultrasound. She was investigated through several blood 
tests; namely a full blood count, inflammatory markers, 
INR, haematinics, serum copper as well as 
caeruloplamin and alpha-antitrypsin levels. An 
autoimmune screen, viral screen, leishmaniasis screen 
and serum protein electrophoresis were also negative, 
as was a trephine biopsy. No abnormalities were 
detected.  
As the cause of the hepatomegaly was obscure, a 
liver biopsy was arranged; this showed sinusoidal 
dilatation suggestive of portal vein thrombosis or 
Budd-Chiari syndrome. CT scan confirmed portal and 
splenic vein thrombosis but the superior mesenteric 
vein was patent. The patient was started on 
anticoagulants, with a target INR of 2-2.5. A 
thrombophilic screen was done; this confirmed protein 
S deficiency. 
An oesophagogastroduodenoscopy (OGD) was 
performed, which showed Grade B oesophageal 
varices, gastric varices and portal hypertensive 
changes. In view of this, the patient was started on 
propranolol. She remained clinically stable for four 
years and was followed up by repeat OGDs. 
Four years after presentation, a follow-up OGD 
showed progression of the oesophageal varices to 
Grade C, red wale signs, and small gastric ulcers. The 
varices were banded and the patient was started on a 
proton pump inhibitor (PPI). 
The patient experienced her first upper GI bleed 
five years after her initial presentation. An emergency 
OGD showed Grade C varices with red wale signs, 
requiring banding 5 times. Warfarin was omitted 
despite an INR which was almost within the target 
range, and maximal PPI doses were administered: 
omeprazole 40mg bd IV. She was started on 
piperacillin-tazobactam 4.5mg tds IV and an octreotide 
pump, set at a rate of 2.5mcg/hr for a total of five days.  
The patient scored 6 on the Rockall score, and 
was in fact managed at the Intensive Care Unit. She 
required several transfusions of packed red cells and 
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fresh frozen plasma in view of anaemia and 
persistently elevated INR. 
During the same admission, she had further 
episodes of fresh bleeding; a second emergency OGD 
showed oesophageal ulcers, prominent gastric varices 
and signs of recent bleeding. She was kept on maximal 
PPI doses and started on sucralfate 1g qds po, as well 
as terlipressin 1mg tds IV. 
The patient was referred for emergency surgery, and a 
mesentero-right-common-iliac shunt was performed. 
She did considerably well in the post-operative period, 
and her ascites was controlled with diuretics. A 
haematological consultation advised testing for Janus 
kinase (JAK)-2 
gene mutation; this was positive, suggesting the 
presence of a myeloproliferative disorder.  
She was discharged on subcutaneous enoxoparin, 
with regular follow-up from the gastrointestinal and 
haematological point of view. 
 
Discussion 
Aetiology 
 Portal vein thrombosis as a complication of 
cirrhosis and hepatocellular carcinoma has long been 
recognized.
2-3
 Over the years, it has been shown that 
PVT can also occur as a cause of several 
thrombophilic states and local abdominal conditions. 
Some studies have shown the involvement of multiple 
factors in the development of PVT.
4
 
 As shown in Table 1, prothrombotic states can be 
inherited or acquired. Inherited thrombophilias include 
genetic disorders such as factor V Leiden mutation, 
factor II gene mutation, protein C deficiency, protein S 
deficiency, antithrombin III deficiency and methylene-
tetrahydrofolate-reductase (MTHR) gene mutation.
5-7
 
 Acquired thrombophilias include primary 
myeloproliferative disorders such as polycythaemia 
rubra vera; PVT may actually be the first manifestation 
of this disease.
8
 Other acquired prothrombotic states 
include paroxysmal nocturnal haemoglobinuria, 
hyperhomocysteinaemia, antiphospholipid syndrome, 
increased factor III levels and thrombin activatable 
fibrinolysis inhibitor (TAFI) gene mutation.
9-12
 
A variety of intra-abdominal inflammatory conditions 
may lead to PVT. These include pancreatitis and local 
injury to the portal vein, for example after abdominal 
trauma or surgery.
13-14
 Uncommonly, portal vein 
thrombosis may occur as a complication of liver 
transplantation.
15 
 
Pregnancy, use of oral contraceptives, chronic 
inflammatory diseases and malignancies represent an 
increased risk in patients with prothrombotic states.
16
 
Other aetiological agents include infection with 
cytomegalovirus and Bacteroides fragilis,
17-18
 while 
approximately 10-30% of cases are idiopathic.
16
 
 
Table 1: Aetiology of PVT 
 
 
 
 
Inherited Prothrombotic state 
- Protein C deficiency 
- Protein S deficiency 
- Antithrombin III deficiency 
- Factor V Leiden mutation 
- Factor II gene mutation 
- Methylene-tetrahydrofolate-reductase (MTHR) 
gene mutation 
Acquired Prothrombotic state 
- Primary myeloproliferative disorder (e.g. 
polycythaemia rubra vera) 
- Paroxysmal nocturnal haemoglobinuria 
- Hyperhomocysteinemia 
- Antiphospholipid syndrome 
- Increased factor VIII levels 
- Thrombin activatable fibrinolysis inhibitor (TAFI) 
gene mutation 
Intra-abdominal inflammation 
- Pancreatitis, appendicitis, diverticulitis 
- Portal vein injury e.g. abdominal trauma, surgical 
procedures 
Portal hypertension 
- Liver cirrhosis 
- Budd-Chiari syndrome 
Malignancy 
- Hepatocellular carcinoma 
- Pancreatic carcinoma 
Infections 
- Cytomegalovirus 
- Bacteroides fragilis  
Pregnancy  
Drugs (e.g. oral contraceptives) 
Idiopathic 
37
  
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 25 Issue 03 2013                                                                                                 
 
 
 
Presentation 
The clinical presentation of PVT may be acute or 
chronic. This classification is not so clear-cut, as there 
is no definitive time frame which distinguishes the two. 
Studies have generally considered the presentation to 
be acute if symptoms develop less than 60 days prior 
to hospital assessment.
19
 PVT is also regarded as acute 
if imaging has ruled out the presence of significant 
collaterals and there is no evidence of portal 
hypertension.  
Acute PVT is characterised by abdominal pain 
and nausea, though it may also be asymptomatic. 
Symptom severity depends on the rapidity and extent 
of the thrombosis. Involvement of the superior 
mesenteric vein may lead to bowel infarction; patients 
may then present with haematochezia, fever, rebound 
tenderness, and ascites. Such a complication is 
associated with a poor prognosis.
20
 Acute PVT may 
then undergo spontaneous resolution, or progress to 
chronic thrombosis. 
Chronic PVT presents with the complications of 
portal hypertension, including variceal bleeding 
(which is usually well-tolerated), splenomegaly or 
hypersplenism. 
16
 Patients may complain of abdominal 
discomfort as a cause of the splenomegaly. Chronic 
PVT may also be asymptomatic and discovered 
incidentally on imaging.  
The presence of cirrhosis, cancer and mesenteric 
vein thrombosis are negative prognostic factors. In fact, 
studies have shown that mortality is influenced more 
by associated disease rather than variceal bleeding per 
se.
4 
 
Investigations 
The investigation of choice is abdominal 
ultrasound. Sonographic findings include the presence 
of solid echoes within the portal vein and 
demonstration of a portal cavernoma.
21 
Additional 
information can then be obtained through other non-
invasive imaging modalities, including doppler 
ultrasound, CT scan, magnetic resonance angiography 
and endoscopic ultrasound.
22-23
  
In our patient, while abdominal ultrasound 
revealed splenomegaly, it was the CT scan which 
clinched the diagnosis of PVT. CT scan can also be 
used to differentiate between recent and old 
thrombosis; the presence of portosystemic collaterals 
and cavernoma formation are both suggestive of old 
thrombosis.
24
 
The next step is a thorough investigation of the 
cause of the thrombosis. Local abdominal factors can 
be identified through imaging; investigation for a 
systemic cause, including myeloproliferative disorders 
and prothrombotic tendencies, is carried out through 
blood tests. 
(24)
 Identification of the aetiological agent 
is vital, as the underlying condition may require 
specific treatment, and will influence the use and 
duration of anticoagulation.
25
 
In our patient, investigations for the presence of 
cirrhosis and for local abdominal causes of thrombosis 
were negative. A thrombophilic screen then confirmed 
protein S deficiency, and a positive test for JAK-2 
gene mutation suggested the presence of a 
myeloproliferative disorder. 
 
Treatment  
The aim of the treatment is two-fold: to prevent or 
reverse thrombus advancement in the portal venous 
system, and to treat any complications that may arise.
25 
Recommendations on the use of anticoagulation 
differ in acute and chronic PVT. While several studies 
have supported the role of anticoagulation in patients 
with acute PVT, 
26
 little information exists on the 
duration and extent of anticoagulation. It has been 
suggested that patients with a self-limiting course of 
PVT, such as acute pancreatitis, should be given a 
course of 3-6 months.
25
 On the other hand, 
anticoagulation can be continued in patients with 
prothrombotic tendencies, a family history of venous 
thrombosis or confirmed extensive thrombosis.  
Thrombolytic therapy has also been shown to lead 
to the resolution of acute PVT. 
27 
Studies have reported 
the use of thrombolytics such as recombinant tissue 
plasminogen activator, both systemically and through 
a catheter-directed infusion.
16
 These techniques have 
been very promising with regard to resolution of 
thrombus, resulting in improved symptomatology and 
avoidance of bowel resection.
28
 However, they have 
had a very high rate of major complications, including 
bleeding. It was thus recommended that thrombolysis 
is reserved for patients with severe disease, while a 
more conservative approach should be taken for others. 
The use of anticoagulation in chronic PVT is 
more controversial, due to the presence of varices as a 
complication of portal hypertension. Nevertheless, it 
has been shown that the benefit-risk ratio in such a 
scenario favours the use of anticoagulant therapy. 
29
 In 
the case presented above, the patient was in fact kept 
on life-long anticoagulation.  
Management of the complications of PVT is 
mostly concerned with prophylaxis and treatment of 
gastro-oesophageal variceal bleeds. This has mostly 
been studied in patients with portal hypertension and 
cirrhosis, rather than isolated PVT. The use of beta-
blockers as prophylaxis in patients with varices, has 
successfully reduced the rate of the first variceal bleed, 
and recent studies have shown that variceal band 
ligation (VBL) is just as effective.
30
 Both medical 
therapy and VBL are also equally effective in 
secondary prevention of variceal bleeds.
 31
 
There remains a lack of information on whether 
one can extrapolate such data to patients with PVT. It 
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has been suggested that beta blockers will theoretically 
decrease splanchnic blood flow which may lead to 
progression of thrombosis,
25
 however there is no 
evidence for this, as yet. In the case presented above, 
the patient was kept on beta-blockers, and VBL was 
performed as primary prophylaxis. Her first episode of 
variceal bleeding occurred five years as presentation, 
and this was once again treated with banding. 
The role of decompressive shunt surgery in PVT 
is also not clear. Indications include failed endoscopic 
therapy, and symptomatic hypersplenism.
24
 
Techniques include a selective distal splenorenal shunt 
(Warren Zeppa) or a mesenteric left portal bypass (Rex 
shunt). Liver transplantation is indicated rarely in 
patients with complications of PVT that cannot be 
controlled through conservative measures or shunt 
surgery.  
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